Conquer Cancer through AI

Lunit

DISCLAIMER

This presentation has been prepared by Lunit Inc. solely for information purposes. The information contained in this presentation has not been independently verified. No representation or warranty express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or any opinion contained herein. The information contained in this presentation should be considered in the context of the circumstances prevailing at the time and will not be updated to reflect material developments that may occur after the date of the presentation. Neither Lunit Inc. nor any of its affiliates, officers, directors or advisors shall have any liability whatsoever (in negligence or otherwise) for any loss arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. This presentation is being communicated only to persons who have professional experience in matters relating to investments and to persons to whom it may be lawful to communicate it (all such persons being referred to as "relevant persons"). This presentation is only directed at relevant persons and any investment or investment activity relating to this presentation is only available to relevant persons or will be engaged in only with relevant persons. Solicitations resulting from this presentation will only be responded to if the person concerned is a relevant person. Other persons should not rely or act upon this presentation or any of its contents. This presentation does not constitute or form part of an offer, invitation or recommendation to purchase or subscribe for any securities, and no part of it shall form the basis of or be relied upon in connection with any contract, commitment or investment decision in relation to any securities. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted. The presentation may contain statements that reflect Lunit Inc.'s beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond Lunit Inc.'s control. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Lunit Inc. does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of this presentation. Certain data in this presentation was obtained from various external data sources, and Lunit Inc. has not verified such data with independent sources. Accordingly, Lunit Inc. makes no representations as to the accuracy or completeness of that data, and such data involves risks and uncertainties and is subject to change based on various factors. You agree to keep the contents of this presentation strictly confidential. All or any part of this presentation may not be taken away, reproduced, redistributed or retransmitted in any manner. By attending this presentation, you are agreeing to be bound by the foregoing limitations.

Conquer Cancer through AI

HQ Seoul | New York | Amsterdam

About Lunit

Since 2013 | 1st Generation Medical AI Company | Listed in KOSDAQ since 2022

Global Investors

Backed by leading global investors

- Raised $122M while unlisted

Foreign investment =$73M 60%

- 9% of global shareholders after IPO
  → Top 11% of KOSDAQ listed 1,800 companies in Korea

GUARDANT, FUJIFILM, 君联资本 LEGEND CAPITAL, HealthQuest CAPITAL, TYBOURNE, CASDIN CAPITAL, SoftBank Ventures Asia

Global Partners

Established partnerships with industry giants

Chosen by leading medical device companies

FUJIFILM, PHILIPS, IBM, GE Healthcare, HOLOGIC, SECTRA, AGFA HealthCare

Chosen by leading bio companies

GUARDANT

Multiple global pharmas

Industry Leader

Best-in-class AI technology and products

- Unprecedented "AA-AA" highest level in technology assessment among healthcare companies
- Best performance proven by direct comparison with global competitors in various studies

- Highest market cap. among listed medical AI companies (2025.06)

Market Cap. of medical AI companies in Korea



5x higher than 2nd place company

Commercial Success

Successfully scaling out revenue growth

- High revenue growth with 207% CAGR (2019 - 2024)
- Lunit INSIGHT (X-RAY)
  → First company globally to exceed $8M in sales
- Volpara revenue consolidation (2024.05~)



Unit : $ Million (1$=1,300₩)

Company Overview

Core Competence

Best-in-Class A.I.

Global leader in AI technology

- Top-tier proprietary AI technology
- 30+ papers presented in top AI conferences
- Large-scale medical data for R&D (N = +4 million cases)

Top Ranked in AI Competitions

2015 Main Task (CLS-LOC) IMAGENET	1	Microsoft
	5	Lunit
	7	Google
2016 MICCAI Grand Challenge – Tumor Proliferation Assessment	1	Lunit
	2	IBM
	3	Microsoft
2017 Camelyon (CAMELYON17)	1	Lunit
	2	Harvard Univ
	3	Eindhoven Univ. of Tech

Global Recognition

International spotlight

- The **only Korean company** spotlighted by World Economic Forum, CB Insights

WORLD ECONOMIC FORUM — **2020 / 2022 - 2025** TECHNOLOGY PIONEER / GLOBAL INNOVATOR / ASSOCIATE PARTNER

2017 AI 100 Lunit — **2017** CB Insights AI 100

2019 Digital Health 150 Lunit CB INSIGHTS — **2019 / 2020 / 2021** CB Insights DIGITAL HEALTH 150

Forbes, Newsweek, BBC, FIERCE Biotech, MIT Technology Review

Medical Expertise

Industry leading clinical studies

- 15+ full-time board-certified physician
- 10+ million medical data collected for AI training
- Strong academic validation leading to high credibility

+460 Publications in Major Peer-reviewed Journals & Abstracts

Journal of Clinical Oncology, THE LANCET Digital Health, JAMA Oncology, JAMA Network Open, ASCO, EJC, European Radiology, SCIENTIFIC REPORTS, ESMO, AACR, Radiology, RSNA, Clinical Infectious Diseases, sitc, USCAP

+100 Research Partnerships

Massachusetts General Hospital, Stanford Medicine, Northwestern Medicine, Columbia, Karolinska Institutet, NHS, UCSF, University of Oxford, Brown, University of Cambridge

Company Overview

Conquer Cancer through AI | Increase cancer survival through AI-powered cancer diagnosis and treatment

AI research platform

1 Cancer diagnosis support solutions

Lunit INSIGHT®

+50%

50% more patients can be screened earlier

Flagship
Lunit INSIGHT CXR / MMG

Chest X-Ray



Mammography

Chest CT



3D Mammo (DBT)

2 Cancer treatment support solutions

Lunit SCOPE®

+50%

50% more patients can be eligible for immunotherapy

Flagship
Lunit SCOPE IO

CT / MRI

DNA / RNA



Tissue

Increase Survival of Cancer Patients

Lunit INSIGHT®

2025 INVESTOR RELATIONS

Lunit INSIGHT MMG®



Lunit INSIGHT CXR®

Lunit INSIGHT Value

Higher Reading Accuracy | Better performance than specialists, proven in major studies

Evidence

Extensively validated through studies

+290

Studies/abstracts

THE LANCET Digital Health
JAMA Oncology
Radiology
JAMA Network Open
RSNA
SCIENTIFIC REPORTS
Clinical Infectious Diseases
European Radiology
BIR The British Institute of Radiology
BMC Pulmonary Medicine
AJR
ACTA RADIOLOGICA
JTD
THE LANCET Regional Health Americas
EUROPEAN RESPIRATORY journal

Performance

Clinically proven to show excellence in medical image analysis



CXR reference : Ju Gang Nam,"Development and Validation of Deep Learning–based Automatic Detection Algorithm for Malignant Pulmonary Nodules on Chest Radiographs ", *Radiology* Vol. 290, No. 1(2018):218–228, doi:10.1148/radiol.2018180237
MMG reference : Hyo-Eun Kim, "Changes in cancer detection and false-positive recall in mammography using artificial intelligence: a retrospective, multireader study", *The Lancet Digital Heath* Vol 2, No. 3(2020):e138-e148, doi:/10.1016/S2589-7500(20)30003-0

Lunit INSIGHT Value

Real World Evidence | Building solid evidence through prospective studies

Study Method

What is prospective study?

Study designed

Retrospective | **Prospective**

Outcome is measured after the baseline state of the subjects is determined and controlled intervention applied.

Reliability ↑	Data quality ↑
Bias ↓	Recall errors ↓

Higher possibility to receive **reimbursement** if backed by prospective studies

Lunit INSIGHT CXR

Flagship prospective CXR study

10,476 Patients with chest X-Ray
RCT study on 'lung nodule detection rate' at Seoul National University Hospital (Korea)

Outcome	Detection rate of actionable lung nodules	Detection rate of malignant lung nodules
A Group (n=5238) Radiologist + AI	31 (0.59%)	8 (0.15%)
B Group (n=5238) Radiologist only	13 (0.25%)	0 (0.0%)

Radiology

Large-scale Prospective RCT*

***Randomized Controlled Trial**
: Research method in which subjects are randomly divided into control and experimental groups for comparison

Lunit INSIGHT MMG

Flagship prospective MMG study

55,579 women screened for breast cancer
Study on 'Double Reading' by Karolinska Institutet (Sweden)

Outcome	Detection rate of cancer per 1,000 women	Recall rate per 1,000 women
1 Radiologist + Lunit INSIGHT MMG	4.3	28
2 Radiologists	4.1	29.3
Lunit INSIGHT MMG	4.1	15.5

THE LANCET Digital Health

Large-scale Prospective Study

Lunit INSIGHT Business

Current Commercialization Status

Usage

Number of paying sites worldwide [1]

+6,400

Portion of revenue from Overseas	77%
Lunit Users among Top 10 Hospitals in Korea [2]	7
Chest X-Ray exams in Korea[3] Analyzed by Lunit INSIGHT CXR 2021	10%
Lunit INSIGHT MMG Users among 47 Large Hospitals in Korea 2025	57%

1) Excludes demo and research use; only commercial sales
2) Newsweek. World's Best Hospitals – South Korea. 2020;
3) Source: KOSTAT.go.kr Appx. 40M Chest X-ray exams performed annually in Korea

Partner Testimonials

"First AI company collaboration for our x-ray business"
— General Manager K✳✳

GE Healthcare

"This is actually **out first AI company collaboration for our x-ray business. The offering will be available on all of GE digital, fixed, and mobile, and even fluoroscopy.** Leveraging the long-term established expertise, that GE has on x-ray equipment in combination with Lunit's technology will help to keep up with the customer needs, care deeply about patients and diagnosing physicians or radiologists."

"Felt very high customer satisfaction"
— Global Marketing Manager M✳✳

FUJIFILM

"In Japan especially, many of the elder people cannot move from home to the clinic to take x-ray. Our x-ray with Lunit AI can visit to take x-ray immediately at home, so it is a significant difference. After we used Lunit AI in the market, I didn't have any complaints. From Fujifilm's standpoint, whatever AI lunit made has a very high quality, so **we would want to implement it in our x-ray system or PACS system.** Customers have already started to use AI and expect more support."

"Lunit has both strong clinical record and national scalability"
— Global Software Product Manager P✳✳

AGFA HealthCare

"**Lunit has a strong clinical validation track record and is registered in Europe and also more than 19 countries, making it an excellent partner for developing solutions that bring our customers intelligent and definitive answers to their daily needs.** We believe that the integration of Lunit's AI in Agfa's advanced medical imaging workstation will help facilitate more effective clinical workflows in various hospital situations."

Lunit INSIGHT Superior Performance

Key Success Factor: Proven to Be Best-in-Class

Accuracy

Superior Performance

JAMA Oncology

Salim, et al. JAMA Oncol. 2020 Aug 27.

IF 24.799[1]

Karolinska Institutet

Comparing 3 Commercial Mammography AI

Retrospective analysis of 8 years of mammography screening

Compared AI screening performance with data from 739 breast cancer-diagnosed women and 112,924 healthy women

	Lunit	Company A	Company B
AI	Lunit INSIGHT MMG	Algorithm A	Algorithm B
Sensitivity	81.9%	67.0%	67.4%
Accuracy (ROC AUC)	95.6%	92.2%	92.0%

1) Impact factor, Top 7 among Oncology Journals

Proven superior performance compared to competitors

Research

Robust Research (SCIE Journals[2])

Modality	Company (Country)	# of Journals
Chest X-Ray	Lunit	64
	Qure.ai	21
	Annalise.ai	9
	Oxipit	3
	Zebra	0
	Others (>10)	None
Mammography	Lunit	58
	ScreenPoint	15
	DeepHealth	2
	Zebra	1
	Others (>10)	None

2) SCIE(Science Citation Index Expanded): Citation index originally produced by the Institute for Scientific Information and created by Eugene Garfield

Robust research with strong clinical evidence in peer-reviewed journals

Partnership

Larger Market Access



Global X-Ray Device Market



Global Mammography Market



Global Reading Software (PACS) Market

Lunit(Partnership Signed) | Zebra Medical Vision | Screenpoint

Access to 50% of market share through global partnership

Lunit INSIGHT Strategy

Next Step Becoming global standard of care by B2G expansion and successful reimbursement

B to G	National Cancer Screening Programs	Reimbursement	Active Reimbursement in Japan/Korea, Expanding into Other Markets	Direct Sales	Expansion into Direct Sales

First Case

Selected into Australia's National Breast Cancer Screening Program

NSW GOVERNMENT | BreastScreen NSW

BSNSW (BreastScreen New South Wales)

: A free national breast cancer screening program in NSW (MMG every 2 years to women over 40). The first case globally in which an AI-based solution is being applied in a national cancer screening program.

Expansion

+10 countries in discussion, B2G business expansion expected in near-future



Europe

AI can reduce burden caused by Double Reading in Europe

Outcome	Detection rate of cancer per 1,000 women	Recall rate per 1,000 women
1 Radiologist + Lunit INSIGHT MMG	4.3	28
2 Radiologists	4.1	29.3
Lunit INSIGHT MMG	4.1	15.5

Possibility of reimbursement in Europe ▲ ▲

EU, 암 정복 위해 우선 '조기 진단'에 힘 쓴다

"2025년까지 대상 인구 90% 유방암·자궁경부암·결장 직장암 검진 받을 수 있도록 한다"

최윤수 기자 | jjysc0229@yakup.com 기자가 쓴 기사 더보기 입력 2022.08.29 06:00 수정 2022.08.29 06:01

Korea

Government Regulation ▼ / Support ▲

Eligible to enter the **non-benefit reimbursement market** from
Lunit INSIGHT CXR: 2024.03 ~
Lunit INSIGHT MMG: 2024.3Q ~

매일경제 2023.04.04. 네이버뉴스

혁신의료기기 시장에 선진입 후 평가받는다...'혁신급여'도 도입

우선 시장에 진입하게 해달란 업계 목소리가 있었다. 복지부 관계자는 "이번 선진입, 후평가 안은 의료법·국민건강보험법 등 법률 개정과 사회적 논의가 필요한 사항으로, 단기적으로 혁신...

혁신 의료기기 규제완화 확대...민간·정부 R&D 10조원까지 확대

등 혁신 기술 의료기기가 신속히 시장에 진입할 수 있도록 전용 평가 및 유예 제도를 확대하는 등의 방식으로 규제가 완화된다. 아울러 국내 의료기기에 향후 5년간 민간과 정부가 연구개발(R...

Direct Sales

Lunit X Volpara

RadNet, The US Oncology Network, Community Health Network, University of Rochester, UNC Health, Piedmont Healthcare, AdvocateAuroraHealth, Northwestern Medicine, Centura Health, AHN, US Radiology Specialists, The University of Texas MD Anderson Cancer Center, ProMedica, EWC, UCSF University of California San Francisco, UWHealth, Memorial Sloan Kettering Cancer Center, CDI Diagnostic Imaging, Mayo Clinic ...

Indirect Sales

Modality Vendors

BM - CAPEX Model
Payment per device

FUJIFILM, GE HealthCare, PHILIPS, SAMSUNG

PACS Vendors

BM - OPEX Model
Payment per image

FUJIFILM, GE HealthCare, SECTRA, AGFA

Lunit

Lunit x Volpara

Lunit Acquires Volpara Health (May, 2024)



Volpara HEALTH → Value → Lunit

- Stable revenue (>$30m in ARR in 2024)
- Large-scale data for training (imaging + clinical data)
- Distribution channel in US for Lunit INSIGHT
- KOL engagement in US for autonomous AI
- Enable business development for lung and other cancer screening product suites

Lunit → Value → Volpara HEALTH

- Boost AI capabilities to strengthen all products
- Synergy with Lunit INSIGHT enables faster market penetration of Volpara products
- Distribution of Volpara products in non-US territories
- Enable development of lung cancer and other cancer related screening

Lunit X Volpara

Strong Revenue Growth Driven by Lunit x Volpara Synergy

Accelerated and Sustained Revenue Growth in Cancer Diagnostics Expected from Lunit x Volpara Synergy



Lunit x Volpara

Direct to Patient Business Model: SecondRead AI Gaining Strong Traction in US Market

Traditional Business Model



New Business Model

Provider offers SecondReadAI™ direct to patients for an out-of-pocket fee at registration or point of care.
Revenue per analysis is **x10-20**





SecondReadAI™ Powered by Lunit Expected Opt-in Rate > 50%

Lunit Cancer Screening

Customization AI for Autonomous AI Requires Platform Approach of Data-AI Flywheel Ecosystem

Radiology · Images · Report · Biopsy result · EMR · Risk

Data-AI Flywheel Ecosystem

Screening Center · Radiology Imaging Center · Hospital · Cancer Center · Community Hospital · Laboratory · Hospice

Lunit X Volpara HEALTH

Customers

Pre-visit
Risk Pathways™

Image Acquisition
Live™

Interpretation
Scorecard™



Diagnostic Aid
Lunit INSIGHT™

Follow Up
Analytics™

The US Oncology Network · UNC HEALTH · AdvocateAuroraHealth · UWHealth · Community Health Network · Centura Health · US Radiology Specialists · MD Anderson Cancer Center · PROMEDICA · EWC · UCSF University of California San Francisco · MAYO CLINIC · AHN · RadNet · Northwestern Medicine · Ochsner · Piedmont · RUSH · University of Rochester · Memorial Sloan Kettering Cancer Center · CDI Diagnostic Imaging

Lunit Cancer Screening

Our Future is Autonomous AI

Path to Autonomous AI: Customization of AI Model for Each Customer

Limitation of current AI applications
: Single AI model for all customer



AI customization using data provided from each site



Expected Benefits of Autonomous AI

- Iterative Self-improvement
- Increased Efficiency
- 24/7 Availability
- No Human Errors
- Personalization

Expected Performance with Autonomous AI



Lunit SCOPE®

2025 INVESTOR RELATIONS



Lunit SCOPE IO



Lunit SCOPE uIHC

Lunit SCOPE Development

Personalized Approach Is Key to Cancer Treatment

High Complexity in Cancer

Even cancers in the same organ have
different biological characteristics and prognoses.

Morphological Type	Mutation Type	Tumor Heterogeneity
1,000+	1,000+	10+

WHO's Morphological Classification



Gene Mutations Causing Cancer



KEY: Personalized Treatment by Biomarkers

Traditional: One general treatment for all cancer patients

Biomarker test X → Diagnosis and Treatment → Patients

Response Rate	Survival Period
10 %	3 months

Now & Future: Biomarker-based personalized treatment

Biomarker test: Biopsy, Blood test, DNA test

Results (positive / negative) → Diagnosis and Treatment → Patients

Response Rate	Survival Period
30%	24 months
50%	
60%	
40%	
30%	

Lunit SCOPE Development

Lunit SCOPE: AI-powered Biomarkers for Major Cancer Drugs



Source: Globaldata



Biomarker Landscape

Targeted Small Molecules	ADCs, mAbs, BsAbs	Immunotherapy
$9~10 B	$5~7B	$6~7B
Lunit SCOPE GP	Lunit SCOPE uIHC	Lunit SCOPE IO®

Lunit SCOPE Overview

Lunit SCOPE: AI-powered Biomarkers for Major Cancer Drugs

Lunit SCOPE IO®

Lunit SCOPE uIHC



Lunit SCOPE GP

	Lunit SCOPE IO®	Lunit SCOPE uIHC	Lunit SCOPE GP
Purpose	Biomarkers for IO therapeutics	Biomarkers for ADCs therapeutics	Screening for multiple biomarkers
Key Features	Identification of predictive tissue/cell features (H&E)	Quantification of protein expression level/pattern (IHC)	End-to-end prediction of specific genomic mutations
Potential Applications	CDx biomarkers for IO drugs Complimentary biomarkers	CDx biomarkers for ADC drugs	Prescreening genomic mutations Patient enrollment in clinical trials
Related Therapies	Immune Checkpoint Inhibitors	Targeted therapy - mostly ADCs	Targeted therapy - small molecules

Lunit SCOPE Value

Key Clinical Studies for Lunit SCOPE

Lunit SCOPE IO

High Prediction of Response to Immunotherapy in Lung Cancer

[Regardless of PD-L1 status] ORR - 2.5 times higher

Patient Group	Overall Response Rate
Lunit SCOPE IO Positive	26.8%
Lunit SCOPE IO Negative	11.3%

[PD-L1 1~49% Group] ORR - 6 times higher

Patient Group	Overall Response Rate
Lunit SCOPE IO Positive	22.8%
Lunit SCOPE IO Negative	3.9%

Expanding Lunit SCOPE IO to All Cancer Types

[All cancer types] ORR - 1.7 times higher

Patient Group	Overall Response Rate
Lunit SCOPE IO Positive	26.3%
Lunit SCOPE IO Negative	15.8%

Lunit SCOPE uIHC

uIHC based AI Quantification for Various Antibodies Protein Expression Analysis

Staining (Antibodies)	No. of Negative TC / Positive TC	Cell detection performance (mF1)	TPS classification performance (Accuracy)
TROP2	1243 / 3289	**78.9%**	**94.0%**
MET	3493 / 1134	**80.5%**	**96.0%**
Claudin 18.2	2927 / 74	**72.7%**	**94.0%**
DLL3	2973 / 3	**68.9%**	**100%**
HER3	2768 / 138	**60.9%**	**94.0%**
FGFR2	2358 / 438	**50.8%**	**81.0%**
E-Cadherin	443 / 912	**79.2%**	**90.0%**

uIHC based AI Quantification Shows Predictive Power in HER2

Group	n	ORR, N (%)	PFS, months, median (95% CI)	HR (95% CI)	P
AI-H3-low	11	0	1.4 (1.3-NR)	Ref	< .001
AI-H3-high	19	8 (42.1)	4.4 (4.0-12.0)	0.12 (0.04-0.38)	

Survival Rate: 3x Gap

Lunit SCOPE GP

Prediction of Various Lung Cancer Driver Mutations by Lunit SCOPE GP

	External Validation set			
	N (%)	AUC	Sensitivity	Specificity
***EGFR*-mt**	224 (28.3)	**0.723**	75.5%	52.6%
***KRAS*-mt**	130 (16.4)	**0.721**	86.2%	22.5%
***ALK*-tr**	46 (5.8)	**0.738**	39.1%	81.8%
***ROS1*-tr**	62 (7.8)	**0.609**	14.5%	70.6%
***RET*-tr**	11 (1.4)	**0.683**	18.2%	96.4%
***MET*-ex**	12 (1.5)	**0.849**	83.3%	74.4%
All-WT	277 (35.0)	N/A	15.9%	**99.2%**

EGFR Mutation Subtype Prediction by Lunit SCOPE GP



Lunit SCOPE BM

Business Model Paired with pharma's drug, to generate high sales by active testing before treatment



Lunit SCOPE Commercial Strategy

Commercialization Roadmap: From Pharma Research to Companion Diagnostics (CDx)

Step 1: Biopharma Engagement → **Step 2: Broader Use, RUO Service** → **Step 3: As a CTA** → **Regulatory Approval as CDx** → **CDx Sales for Clinical Use**

Pilot or Bake-off Study

Active Pharma

15+

Translational Research

Active Pharma

10+

Clinical Trial Enrollment

Apply SCOPE in Clinical Trials

Screening patients with SCOPE for patient enrollment in clinical trials OR Analyzing existing clinical trial data with SCOPE

FDA Approval

Drug
Proof of efficacy

Lunit SCOPE
CDx proof of efficacy



Per Test Payment for Clinical Use

Research Revenue: Per Analysis Payment from Pharma Partners

Global Top20 Pharma of 2024 based on oncology drug revenues

1	Merck	11	Astellas
2	BMS	12	Incyte
3	Roche	13	Takeda
4	J&J	14	Gliead
5	AZ	15	Sanofi
6	Novartis	16	BeiGene
7	Pfizer	17	Daiichi
8	Amgen	18	Bayer
9	Eli Lilly	19	GSK
10	Abbvie	20	Teva

We are engaged with

15+

Lunit SCOPE Revenue Trend (RUO Sales)

Clinical collaborations with big pharma to generate research revenue

$



2027 ~ : FDA Approval



Exponential increase in revenue
Approved as CDx product; authorized for reimbursement



Lunit SCOPE Market

Cancer Biomarker Market

$27B+

Target Market

$10B+

Lunit SCOPE Channels

Strong Traction with Major Industry Vendors for Future Distribution Scalability

Pathology Labs

Top 5 Anatomic Pathology Labs Based on Revenue	
1	Labcorp
2	Quest
3	Sonic
4	Neogenomics
5	Pathgroup



Staining Component

Antibody Manufacturer

Leica BIOSYSTEMS, Roche, Agilent

Digitization Component

Scanner Manufacturer

Leica BIOSYSTEMS, Roche, 3DHISTECH, PHILIPS, HAMAMATSU

Viewing Component

Path-PACS Manufacturer

SECTRA, Leica BIOSYSTEMS, indica labs, PHILIPS, Roche

Example companies:

Among Top5 Labs, We are engaged with - as well as other key CROs — **2**

Among Top5 antibody makers, We are engaged with — **2**

Among Top5 platforms, We are engaged with — **3**

Most pathology scanners are compatible with Lunit's AI — **5+**

Lunit Oncology

Next Steps

Cover All Types of Drugs

Lunit SCOPE will be able to cover all types of oncology drugs



Source : Maximize market research PVT. LTD

Multi-omic Biomarkers

Lunit SCOPE will deliver optimal cancer treatment through multi-omics analysis



"Multi-omics"

Drug Discovery & Development

Lunit SCOPE biomarkers shall be applied to drug discovery/development



Conquer Cancer through AI-powered Precision Medicine

Having strong faith that a data-driven approach is the future,

Lunit will be the center of cancer care

Globally become the new standard of care

Personalized Screening / Diagnosis		Personalized Treatment	
Precision Screening	**Precision Diagnostics**	**Precision Treatment**	**Precision Monitoring**
Personalized screening through Lunit INSIGHT	 Lunit INSIGHT	 Lunit SCOPE	 Lunit-based Monitoring

THANK YOU

Lunit

Appendix

Consolidated Financial Statements

Statement of Financial Position

Unit:KRW million

	1H 2025	2024	2023	2022
Current Asset	87,924	111,062	230,418	68,050
Non Current Asset	325,086	324,215	37,503	29,103
Total Assets	**413,010**	**435,277**	**267,921**	**97,153**
Current Liabilities	253,601	252,736	12,794	9,446
Non Current Liabilities	17,545	17,767	20,017	18,797
Total Liabilities	**271,146**	**270,502**	**32,811**	**28,243**
Capital Stock	14,575	14,471	14,351	6,114
Additional paid-in Capital	537,805	526,646	515,518	320,857
Others	691	1,495	181	142
Retained earnings	(411,208)	(377,837)	(294,941)	(258,202)
Total shareholders' equity	**141,864**	**164,774**	**235,110**	**68,910**

Source: DART, Company K-IFRS Audited

Income Statement

Unit:KRW million

	1H 2025	2024	2023	2022
Operating Income	37,077	54,180	25,080	13,866
Operating Cost	78,988	121,833	67,297	64,517
Operating Income(Loss)	**(41,911)**	(67,654)	(42,217)	(50,651)
Financial Income	28,143	19,202	10,257	13,642
Financial Expenses	19,135	34,721	4,764	2,060
Other Income	96	107	80	43
Other Expenses	36	121	119	92
Income(Loss) before Tax	**(32,843)**	(83,187)	(36,764)	(39,118)
Tax Expenses(Income)	225	(758)	35	-
Net Income(Loss)	**(33,068)**	**(82,428)**	**(36,798)**	**(39,118)**

Source: DART, Company K-IFRS Audited